Cemiplimab
A monoclonal antibody that blocks the programmed death receptor-1 (PD-1) on T cells, restoring immune activity against cancer cells. It is approved for the treatment of cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer. Like other checkpoint inhibitors, it can cause immune-related adverse events affecting multiple organ systems.
Terapötik Alanlar
Etki Mekanizması
Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
A monoclonal antibody that blocks the programmed death receptor-1 (PD-1) on T cells, restoring immune activity against cancer cells. It is approved for the treatment of cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer. Like other checkpoint inhibitors, it can cause immune-related adverse events affecting multiple organ systems.
Binds to a specific target antigen on tumor cells or immune cells, triggering immune-mediated destruction through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), or direct signaling inhibition.
Yes, Cemiplimab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297723. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cemiplimab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cemiplimab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cemiplimab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cemiplimab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cemiplimab"></drugfyi-drug>